Blueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023

Rhea-AI Summary

Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call and webcast on February 16, 2023, at 8:00 a.m. ET to announce its fourth quarter and full year 2022 financial results and provide a corporate update. Investors can participate by dialing 844-200-6205 (domestic) or 929-526-1599 (international) using conference ID 286085. The call will also be available for webcast on the company's website, with an archived version accessible for 30 days post-event. Blueprint Medicines focuses on innovative therapies for cancer and blood disorders, leveraging its molecular targeting and drug design expertise.

Positive

• Hosting a live conference call to report Q4 and full year 2022 results may boost investor confidence.
• Ongoing advancements in precision therapies indicate a strong pipeline in the oncology space.

Negative

• None.

CAMBRIDGE, Mass., Feb. 9, 2023 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 16, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.

To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international), and refer to conference ID 286085. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.

About Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-fourth-quarter-and-full-year-2022-financial-results-on-thursday-february-16-2023-301742048.html

SOURCE Blueprint Medicines Corporation

FAQ

When will Blueprint Medicines report its Q4 and full year 2022 financial results?

Blueprint Medicines will report its Q4 and full year 2022 financial results on February 16, 2023.

How can I access the Blueprint Medicines earnings call?

You can access the Blueprint Medicines earnings call by calling 844-200-6205 (domestic) or 929-526-1599 (international) and using conference ID 286085.

Is there a webcast available for the Blueprint Medicines financial results call?

Yes, a webcast of the call will be available on the Blueprint Medicines website under the 'Events and Presentations' section.

How long will the archived webcast of Blueprint Medicines' earnings call be available?

The archived webcast will be available for 30 days following the conference call.

What is the focus of Blueprint Medicines Corporation?

Blueprint Medicines focuses on inventing life-changing therapies for cancer and blood disorders.